August 9, 2022 Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
June 8, 2022 Cerevance to Participate in Panel Discussion During the 2022 BIO International Convention
April 19, 2022 Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
March 31, 2022 Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
September 8, 2021 Neuroscience Drug Development Veteran Mike Poole, M.D., FACP, to Join Cerevance Board of Directors
February 10, 2021 Cerevance Appoints Naidong Ye, Ph.D. as Vice President and Head of Chemistry, Manufacturing and Controls
